Post Conference Perspectives: Immunotherapy Combinations for Unresectable HCC

EP. 1: The Impact of Liver Pathobiology on HCC Treatment Approach

February 1st 2020

EP. 2: IMbrave150 Phase III Design, Results, and Practical Implications

February 1st 2020

EP. 3: The COSMIC-312 Phase III and Other Notable Trials

February 1st 2020

EP. 4: Challenges With Novel Treatment Strategies

February 1st 2020

EP. 5: Immunotherapy in Unresectable HCC

February 1st 2020

EP. 6: IMbrave150 in Unresectable HCC

February 1st 2020

EP. 7: Emerging I-O Combination Trials in Unresectable HCC

February 1st 2020

EP. 8: Sequencing With I-O Combinations in Unresectable HCC

February 1st 2020

EP. 9: Treating Unresectable HCC in the Community

February 1st 2020

EP. 10: Review Period Extended in GIST, Disappointing Findings in Lung Cancer, and More

February 1st 2020

EP. 11: FDA Approval in HER2+ Breast Cancer, Priority Review in NSCLC, and More

February 1st 2020

x